Why Emerging Nicotine Products Are Creating New Questions for Insurers
The nicotine marketplace has changed dramatically over the past decade.
Traditionally, insurance underwriting relied on a relatively simple distinction: applicants were generally classified as either smokers or non-smokers. This approach reflected decades of evidence demonstrating the substantial health risks associated with combustible tobacco use and the elevated mortality and morbidity risks observed among smokers.
Today, however, the emergence of nicotine pouches, vaping products, heated tobacco products, and other smoke-free nicotine alternatives is challenging these traditional classifications.
As consumers increasingly move away from combustible tobacco products, insurers face an important question: should all nicotine use be treated equally, or should underwriting frameworks evolve to reflect differences in product type and potential exposure?
A growing body of research suggests that this issue may become increasingly important for insurers, regulators, and policymakers alike.
The Historical Approach to Nicotine and Insurance
Life and health insurers have traditionally used smoking status as a key risk indicator.
The rationale is straightforward. Smoking is strongly associated with increased risks of cancer, cardiovascular disease, respiratory illness, and premature mortality. As a result, smokers typically face higher premiums than non-smokers.
This approach has generally worked well when combustible cigarettes dominated nicotine consumption.
However, the emergence of smoke-free nicotine products has introduced greater complexity into underwriting decisions.
An individual who exclusively uses nicotine pouches may have a very different exposure profile from someone who smokes a pack of cigarettes every day. Yet many underwriting systems continue to classify both individuals within the same broad nicotine-user category.
This raises questions about whether traditional underwriting models remain fit for purpose in a rapidly evolving nicotine landscape.
The Challenge of Product Diversity
One of the key challenges for insurers is that nicotine use is no longer a single, uniform behaviour.
Consumers now use nicotine through a variety of products with different delivery mechanisms, exposure profiles, and patterns of use.
Combustible cigarettes involve inhalation of smoke and exposure to thousands of combustion-related toxicants. Nicotine pouches deliver nicotine orally without combustion or tobacco leaf. Vaping products aerosolise nicotine-containing liquids, while heated tobacco products operate through a different mechanism again.
These differences do not necessarily eliminate health risks, but they may influence the nature and magnitude of those risks.
For insurers, the central challenge is determining whether underwriting frameworks should continue treating all nicotine use as equivalent or whether greater differentiation is warranted.
The Case for More Nuanced Underwriting
Recent research suggests that a more sophisticated approach may be necessary.
Rather than relying solely on binary smoker versus non-smoker classifications, insurers may increasingly benefit from collecting more detailed information regarding product type, frequency of use, duration of use, and patterns of nicotine consumption.
Enhanced disclosure requirements could help underwriters better understand an applicant’s exposure profile. Verification strategies may also need to evolve as newer nicotine products become more common and traditional indicators of smoking status become less informative.
This does not necessarily imply lower premiums for users of alternative nicotine products. Significant uncertainties remain regarding long-term health outcomes for several emerging product categories.
However, more detailed information could support risk assessments that are more closely aligned with actual exposure rather than broad product categories.
The Importance of Evidence
One reason this debate remains unresolved is that the scientific evidence base continues to evolve.
Smoking-related risks are supported by decades of epidemiological research. By contrast, many smoke-free nicotine products have only emerged within the past decade or two.
While toxicological studies consistently indicate substantially lower exposure to harmful constituents compared with smoking, long-term population-level evidence is still developing.
Insurers therefore face a difficult balancing act.
On one hand, existing evidence suggests important differences between combustible and non-combustible nicotine products. On the other, actuarial models depend heavily on long-term outcomes data that may not yet be available for newer products.
As additional evidence emerges, underwriting practices may continue to evolve accordingly.
Lessons from Risk-Based Regulation
The discussion mirrors broader debates occurring within public health and regulatory policy.
Many regulators are increasingly examining whether nicotine products should be governed according to relative risk rather than through a one-size-fits-all framework.
The same principle may ultimately prove relevant for insurance.
If different nicotine products expose users to different levels of risk, insurers may eventually seek underwriting models capable of reflecting those distinctions while maintaining prudent risk management practices.
Such an approach would not require assumptions about product safety. Rather, it would involve continuously updating risk assessments as new scientific evidence becomes available.
A Future of Greater Differentiation?
The continued diversification of nicotine products suggests that traditional underwriting categories may become increasingly difficult to maintain.
Future underwriting systems may incorporate more detailed disclosure regarding product type, usage patterns, frequency of use, and duration of exposure. Advances in data analytics and risk modelling could also support more granular approaches to nicotine-related risk assessment.
For insurers, this may improve pricing accuracy and strengthen alignment between premiums and actual exposure.
For consumers, it could potentially create a more transparent and evidence-based approach to nicotine-related underwriting decisions.
Whether the industry ultimately moves in this direction remains uncertain. However, the conversation is likely to become increasingly relevant as smoke-free nicotine products continue to gain market share.
Looking Ahead
The emergence of nicotine pouches and other smoke-free nicotine products is creating new challenges for insurance underwriting.
Traditional smoker classifications were developed in a market dominated by combustible tobacco. Today’s nicotine landscape is considerably more diverse, raising important questions about how risk should be assessed and priced.
For insurers, the evolving evidence base highlights the potential value of more nuanced underwriting approaches that incorporate product type, usage patterns, enhanced disclosure requirements, and improved verification methods.
The objective is not necessarily to redefine risk overnight. Rather, it is to ensure that underwriting frameworks remain capable of adapting to scientific evidence, changing consumer behaviour, and a rapidly evolving nicotine marketplace.
As nicotine products continue to diversify, insurers may increasingly find that understanding how nicotine is used becomes just as important as whether nicotine is used at all.
Source
https://jim.kglmeridian.com/view/journals/insm/53/2/article-p135.xml
